Large B-cell lymphoma-IRF4+ in children and young people: time to reduce chemotherapy in a rare malignant mature B-cell neoplasm?
(2024) Blood Advances — Vol. 8, n° 6, p. 1509-1514 (2024)
Files
2024_Huibers_Blood_Adv.pdf
Open Access - Adobe PDF
- 593.63 KB
Details
- Authors
- Abstract
- Since 2022, large B-cell lymphoma with IRF4-rearrangment (LBCL-IRF4+) has been recognized as a definite entity by the World Health Organization (WHO) classification of hematolymphoid tumors. It is characterized by a follicular and/or diffuse growth pattern as well as a strong expression of IRF4, which is due to translocation of IRF4 with an immunoglobulin gene.Essential and desirable diagnostic criteria are set by the WHO, including clinical, morphological, immunophenotypical, and moleculargenetic parameters. [...]
- Affiliations
Citations
Huibers, M., Abla, O., Andrés, M., Balagué, O., Beishuizen, A., Carraro, E., Chiang, A., Csóka, M., David, B.-A., de Ville de Goyet, M., Gilad, G., Hori, D., Kotecha, R. S., Kabickova, E., Klapper, W., Miakova, N., Minard-Colin, V., Nakazawa, A., Pillon, M., et al. (2024). Large B-cell lymphoma-IRF4+ in children and young people: time to reduce chemotherapy in a rare malignant mature B-cell neoplasm? Blood Advances, 8(6), 1509-1514. https://doi.org/10.1182/bloodadvances.2023012109 (Original work published 2024)